Galmed Pharmaceuticals (Galmed Pharmaceuticals) Accumulated other comprehensive income (loss) : $-0.45 Mil (As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Galmed Pharmaceuticals Accumulated other comprehensive income (loss)?

Accumulated other comprehensive income (loss) is the aggregate amount of gains or losses that are not part of retained earnings. Galmed Pharmaceuticals's Accumulated other comprehensive income (loss) for the quarter that ended in Dec. 2023 was $-0.45 Mil.

Galmed Pharmaceuticals's quarterly Accumulated other comprehensive income (loss) increased from Jun. 2023 ($-0.66 Mil) to Sep. 2023 ($-0.61 Mil) and increased from Sep. 2023 ($-0.61 Mil) to Dec. 2023 ($-0.45 Mil).

Galmed Pharmaceuticals's annual Accumulated other comprehensive income (loss) declined from Dec. 2021 ($-0.17 Mil) to Dec. 2022 ($-0.75 Mil) but then increased from Dec. 2022 ($-0.75 Mil) to Dec. 2023 ($-0.45 Mil).

Galmed Pharmaceuticals Accumulated other comprehensive income (loss) Historical Data

The historical data trend for Galmed Pharmaceuticals's Accumulated other comprehensive income (loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Galmed Pharmaceuticals Accumulated other comprehensive income (loss) Chart

Galmed Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accumulated other comprehensive income (loss)

Get a 7-Day Free Trial

0.04

0.27

-0.17

-0.75

-0.45

Galmed Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Accumulated other comprehensive income (loss)	Get a 7-Day Free Trial															-0.75	-0.65	-0.66	-0.61	-0.45

Galmed Pharmaceuticals Accumulated other comprehensive income (loss) Calculation

Accumulated other comprehensive income (loss) is the aggregate amount of gains or losses that are not part of retained earnings.

Galmed Pharmaceuticals Accumulated other comprehensive income (loss) Related Terms

Thank you for viewing the detailed overview of Galmed Pharmaceuticals's Accumulated other comprehensive income (loss) provided by GuruFocus.com. Please click on the following links to see related term pages.

Galmed Pharmaceuticals (Galmed Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Galmed Pharmaceuticals Ltd (NAS:GLMD) » Definitions » Accumulated other comprehensive income (loss)

Comparable Companies

Traded in Other Exchanges

GPH:Germany

Address

16 Tiomkin Street, Tel Aviv, ISR, 6578317

Website

https://www.galmedpharma.com

Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product, aramchol, is a disease-modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-hepatitis. Aramchol affects liver fat metabolism and has been shown in a Phase IIa clinical study to reduce liver fat content, as well as improve metabolic parameters associated with Nonalcoholic steatohepatitis.